Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study

To deal with the COVID-19 pandemic, a mass vaccination campaign was started in European countries on 27 December 2020. The first vaccine available to immunize healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine. While many studies have shown a high antibody response after the second vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Francesco Paolo, Stefanizzi, Pasquale, Germinario, Cinzia Annatea, Migliore, Giovanni, Vimercati, Luigi, Martinelli, Andrea, Lobifaro, Annamaria, Diella, Giusy, Larocca, Angela Maria Vittoria, Tafuri, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949567/
https://www.ncbi.nlm.nih.gov/pubmed/35335049
http://dx.doi.org/10.3390/vaccines10030417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949567/
https://www.ncbi.nlm.nih.gov/pubmed/35335049
http://dx.doi.org/10.3390/vaccines10030417

Ejemplares similares